{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:14:04Z","timestamp":1792098844072,"version":"4.4.0"},"reference-count":40,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Mundipharma Pty Ltd"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Palliat Med"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Opioid-induced constipation is a common side effect of Oxycodone. Oxycodone\/Naloxone Prolonged Release (OXN PR) mitigates opioid-induced constipation in non-cancer pain, however its evidence is limited in people with pain from advanced cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To demonstrate analgesic non-inferiority, and superiority in reducing constipation for Oxycodone\/Naloxone Prolonged Release (OXN PR) compared to Oxycodone Prolonged Release (Oxy PR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Multi-centre open-label randomised controlled trial comparing OXN PR to Oxy PR over 5\u2009weeks. The primary aim was to demonstrate analgesic non-inferiority of OXN PR compared to Oxy PR. The secondary aim was to demonstrate superiority of constipation reduction in the OXN PR arm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting\/participants:<\/jats:title>\n                    <jats:p>Participants with moderate-severe pain (\u2a7e4\/10) from advanced cancer were eligible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty\u2009seven of planned 96 patients were recruited with the study stopping early due to enrolment challenges during the COVID-19 pandemic. Average pain was \u22121.5 points (95% CI\u2009\u22123.3; 0.4) favouring the OXN PR arm compared to Oxy PR at 5\u2009weeks, meeting analgesic non-inferiority, defined as falling within a one point non-inferiority margin. The OXN PR arm demonstrated less constipation with a significantly lower Bowel Function Index score (\u221224.87 (95% CI 47.54; 2.21),\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.03) compared to Oxy PR. Adverse effect safety profile favoured OXN PR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>OXN PR is non-inferior to Oxy PR in analgesic effectiveness and superior in reducing constipation. These results indicate OXN PR as the choice of opioid preparation in advanced cancer. Future studies may explore adding naloxone to other slow and immediate release opioid preparations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registry:<\/jats:title>\n                    <jats:p>Australian New Zealand Clinical Trials Registry<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number:<\/jats:title>\n                    <jats:p>ACTRN12619001282178<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>URL of trial registry record:<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=377673&amp;isReview=true\">https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=377673&amp;isReview=true<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02692163251362563","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T02:16:19Z","timestamp":1756347379000},"page":"999-1009","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Oxycodone\/naloxone PR versus oxycodone PR in advanced cancer: A multi-centre randomised trial (ENhANCE trial)"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6507-1219","authenticated-orcid":false,"given":"Aaron K","family":"Wong","sequence":"first","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Grobler","sequence":"additional","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0880-8819","authenticated-orcid":false,"given":"Ruwani","family":"Mendis","sequence":"additional","affiliation":[{"name":"Western Health, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-0645","authenticated-orcid":false,"given":"Jennifer","family":"Philip","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0830-4864","authenticated-orcid":false,"given":"Brian","family":"Le","sequence":"additional","affiliation":[{"name":"Melbourne Health, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2021.703165"},{"issue":"7","key":"e_1_3_2_3_2","article-title":"Opioids for cancer pain - an overview of cochrane reviews","volume":"7","author":"Wiffen PJ","year":"2017","unstructured":"Wiffen PJ, Wee B, Derry S, et al Opioids for cancer pain - an overview of cochrane reviews. Cochrane Database Syst Rev 2017; 7(7): Cd012592.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2015.12.340"},{"key":"e_1_3_2_5_2","volume-title":"WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents","author":"World Health Organisation","year":"2019","unstructured":"World Health Organisation. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: World Health Organisation, 2019."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.18356\/9789210014892"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.01.009"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.2.181"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269216311401948"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01415.x"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12646"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269216311418869"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1050"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903483222"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00424-4"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.5414\/CP201646"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/aas.12051"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802584454"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2008.06.012"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902796798"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-10-12"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.06.014"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01780-6"},{"issue":"2","key":"e_1_3_2_24_2","article-title":"Chronic non-cancer pain management and addiction: a review","volume":"12","author":"Genova A","year":"2020","unstructured":"Genova A, Dix O, Thakur M, et al Chronic non-cancer pain management and addiction: a review. Cureus 2020; 12(2): e6963.","journal-title":"Cureus"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4366-z"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-492"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051058"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14123"},{"key":"e_1_3_2_29_2","volume-title":"Australian Public Assessment Report for Oxycodone hydrochloride\/Naloxone hydrochloride","author":"Therapeutic Goods Administration","year":"2010","unstructured":"Therapeutic Goods Administration. Australian Public Assessment Report for Oxycodone hydrochloride\/Naloxone hydrochloride. Canberra: Australian Government Department of Health and Ageing, 2010."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13561"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.101036"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-684X-4-7"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2005.06.002"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.657301"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.3111\/13696990903430481"},{"key":"e_1_3_2_36_2","volume-title":"EORTC QLQ-C30 scoring manual","author":"Fayers PA","year":"2001","unstructured":"Fayers PA, Bjordal K, Groenvold M, et al (eds). EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: EORTC Quality of Life Group, 2001.","edition":"3"},{"key":"e_1_3_2_37_2","unstructured":"Australian and New Zealand College of Anaesthetists. Opioid Dose Equivalence Calculation Table 2021 https:\/\/www.betterpainmanagement.com\/catalog?pagename=Useful-Links (Accessed 5 February 2025)"},{"key":"e_1_3_2_38_2","volume-title":"Proceedings of the international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Editor E9 (R1)","year":"2019","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Editor E9 (R1). Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. In: Proceedings of the international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use, 2019."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2021.12.022"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-017-1745-8"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1060486"}],"container-title":["Palliative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02692163251362563","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02692163251362563","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02692163251362563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:37:44Z","timestamp":1777660664000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02692163251362563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/02692163251362563"],"URL":"https:\/\/doi.org\/10.1177\/02692163251362563","relation":{},"ISSN":["0269-2163","1477-030X"],"issn-type":[{"value":"0269-2163","type":"print"},{"value":"1477-030X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}